|
|
|
| Effect of Atorvastatin on the Expression of Inflammatory Cytokines in Rats with Klebsiella Pneumonia |
| QUE Wei-wei, LI You-tang, WENG Duan-li |
| Longyan First Affiliated Hospital to Fujian Medical University, Longyan Fujian 364000, China |
|
|
|
|
Abstract Objective: To explore the effect of atorvastatin on the expression of inflammatory cytokines in rats with Klebsiella pneumonia. Methods: 90 healthy SPF-grade SD rats were randomly divided into three groups: atorvastatin group, model group and blank group (with 10 rats in each group), 30 rats in each treatment period (3,6,9 d). A rat model of Klebsiella pneumonia was constructed, in which the blank group and the model group were given the same volume of saline, while the atorvastatin group was given 10 ml/kg of atorvastatin by intraperitoneal instillation. The rats were killed on the 10th day after administration, and the lung tissue was extracted to detect the pathological results and the expression of inflammatory cytokines was detected in serum. Results: Lung histopathology showed that lung histopathology and fibrosis were improved in atorvastatin group, and alveolar structure integrity ≥50% and collagen fiber precipitation ≤10% in atorvastatin group indicated that the model was successful. The expression of inflammatory cytokines showed that the levels of IL-6, TNF-α and TGF-β in the atorvastatin group and the model group were significantly increased compared with the blank group, with statistically significant differences(P<0.05). The levels of IL-6, TNF-α and TGF-β in atorvastatin group were lower than those in model group, and the levels of IL-10 in atorvastatin group were higher than those in model group, with statistically significant differences (P<0.05). After 9 days, the levels of IL-6, TNF-α, TGF-β and IL-10 in the atorvastatin group and the model group were higher than those in the blank group, with statistically significant differences (P<0.05). The results of immunological function study showed that WBC, RBC and PLT in orvastatin group and model group were significantly reduced at 3 d compared with the blank group, with statistically significant differences(P<0.05). After 6 and 9 d, WBC, RBC and PLT in atorvastatin group and model group were lower than those in blank group, and WBC, RBC and PLT in atorvastatin group were lower than those in model group, with statistically significant differences(P<0.05). Conclusion: Atorvastatin can significantly improve the immune dysfunction and the expression of inflammatory cytokines in rats with Klebsiella pneumonia.
|
|
Received: 15 February 2023
|
|
|
|
Corresponding Authors:
WENG Duan-li. E-mail: wengduanli_0522@163.com
|
|
|
|
[1] Yu Y, Jiang H, Ge J.Efficacy and safety of rosuvastatin vs. atorvastatin in lowering LDL cholesterol: A meta-analysis of trials with East Asian populations[J]. Herz, 2020,45(6):594-602.
[2] Huang J, Yao D, Li C.Atorvastatin ester regulates lipid metabolism in hyperlipidemia rats via the PPAR-signaling pathway and HMGCR expression in the liver[J]. Int J Mol Sci, 2021,22(20):1107-1121.
[3] Chao X, Xie L, Wang H.The characteristic of virulence, biofilm and antibiotic resistance of Klebsiella pneumoniae[J]. Int J Environ Res Public Health, 2020,17(17):6278-6288.
[4] Xu K, Chen W, Ye W.Atorvastatin inhibited TNF-α induced matrix degradation in rat nucleus pulposus cells by suppressing NLRP3 inflammasome activity and inducing autophagy through NF-κB signaling[J]. Cell Cycle, 2021,20(20):2160-2173.
[5] Wyres KL, Lam MMC, Holt KE.Population genomics of Klebsiella pneumoniae[J]. Nat Rev Microbiol, 2020,18(6):344-359.
[6] Honda T, Inagawa H.Suppression of inflammatory cytokine genes expression in vascular endothelial cells by super-low dose lipopolysaccharide-activated macrophages[J]. Anticancer Res, 2022,42(8):4049-4054.
[7] Bing R, Gartling GJ, Branski RC.Macrophages alter inflammatory and fibrotic gene expression in human vocal fold fibroblasts[J]. Exp Cell Res, 2022,419(1):113301.
[8] Choby JE, Howard-Anderson J, Weiss DS.Hypervirulent Klebsiella pneumoniae-clinical and molecular perspectives[J]. J Intern Med, 2020,287(3):283-300.
[9] Shen S, Shi Q, Hu F.The changing face of Klebsiella pneumoniae carbapenemase: in-vivo mutation in patient with chest infection[J]. Lancet, 2022,399(10342):2226.
[10] Arkaban H, Kalantar-Neyestanaki D, Akbarizadeh MR, et al.Recent advances in nanotechnology for the management of Klebsiella pneumoniae-related infections[J]. Biosensors (Basel), 2022,12(12):1155. |
|
|
|
